Cataracts Clinical Trial
Official title:
Evaluation of Clinical Outcomes in China for the TECNIS Symfony® Toric Intraocular Lens Model Series ZXT
Verified date | February 2024 |
Source | Johnson & Johnson Surgical Vision, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, single-center, single-arm, open-label, clinical study of the investigational TECNIS Symfony® Toric IOL. The study will enroll up to 100 subjects from a single investigative site in China. The subjects will be followed for 12-months postoperatively.
Status | Completed |
Enrollment | 82 |
Est. completion date | January 24, 2024 |
Est. primary completion date | January 24, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female patients at least 18 years of age 2. Have a cataract in one or both eyes, with planned phacoemulsification with intraocular lens implantation 3. Have estimated postoperative visual acuity of at least 20/25 Snellen (0.8 decimal) in the eye to be implanted per surgeon estimate \ 4. Regular corneal astigmatism and predicted postoperative residual astigmatism of less than 1.00 D after implantation with a toric intraocular in the study eye(s) 5. Availability, willingness and sufficient cognitive awareness to understand the purpose of the examination procedures and comply with postoperative visits that are required by the study protocol 6. Voluntary participation indicated by the study informed consent form (ICF) signed by the patient or legal guardian. Exclusion Criteria: 1. Concurrent participation or participation in any other clinical study within 30 days prior to the preoperative visit 2. Ocular disease (other than cataract) that may significantly affect postoperative vision, such as visually significant keratopathy, macular lesions, diabetic retinopathy, chronic or severe uveitis, etc. 3. Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery, including prophylactic peripheral iridotomies and peripheral laser retinal repairs 4. Irregular corneal astigmatism 5. Inability to achieve keratometric stability for contact lens wearers (as defined in Section 10.3 Preoperative Procedures) 6. Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause visual acuity loss to a level worse than 20/30 Snellen (0.67 decimal) during the study 7. Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects 8. Use of systemic or ocular medications that may affect vision, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery) 9. Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.). Note: controlled ocular hypertension without glaucomatous changes (optic nerve cupping and visual field loss) is acceptable. 10. Planned monovision correction (one eye designated for near correction). 11. Patients who are pregnant or nursing. 12. Severe or unstable systemic disease that may affect the heart, liver, kidney, lung, endocrine (including thyroid insufficiency), blood, or psychoneurological dysfunction 13. Any other systemic or ocular disease that, in the opinion of the investigator, may affect the patient's eligibility for the study, affect visual acuity or may require surgical intervention during the course of the study (e.g., macular degeneration, cystoid macular edema, diabetic retinopathy, etc.). |
Country | Name | City | State |
---|---|---|---|
China | The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou |
Lead Sponsor | Collaborator |
---|---|
Johnson & Johnson Surgical Vision, Inc. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | percentage of eyes that are measured at the 1-week postoperative visit to demonstrate =10º change from the intended IOL axis at the end of surgery | 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06005675 -
User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL
|
||
Active, not recruiting |
NCT01382641 -
Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery
|
Phase 4 | |
Completed |
NCT01382823 -
Laser Cataract Surgery With the Femtosecond Laser Technology
|
Phase 4 | |
Completed |
NCT05991960 -
Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL
|
||
Active, not recruiting |
NCT05574959 -
Clinical Investigation of the TECNIS® Next-Generation Intraocular Lens, Model DEN00V
|
N/A | |
Completed |
NCT02492659 -
Clinical Research of Femtosecond Laser-Assisted Cataract Surgery
|
N/A | |
Completed |
NCT01279031 -
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
|
Phase 4 | |
Completed |
NCT01061463 -
Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study
|
N/A | |
Completed |
NCT01001806 -
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT00999492 -
Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront
|
Phase 4 | |
Completed |
NCT01021761 -
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT00542581 -
Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D.
|
N/A | |
Completed |
NCT03708367 -
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
|
N/A | |
Completed |
NCT05575063 -
Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD)
|
N/A | |
Recruiting |
NCT05531292 -
PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002
|
N/A | |
Completed |
NCT05058274 -
Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)
|
||
Recruiting |
NCT02639845 -
Eye Drop Application Monitor, Pilot Study
|
N/A | |
Completed |
NCT01684007 -
A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients
|
N/A | |
Completed |
NCT00827073 -
Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery
|
N/A | |
Completed |
NCT00405730 -
Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo
|
Phase 3 |